Zi-Jian Zhao

Prof. Zi-Jian Zhao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2017 in Microchimica Acta
Verified
Journal Article
Closed access
PDF file
ZYZufu Yao
Zufu Yao
YXYang Xin
Yang Xin
XLXiaobo Liu
Xiaobo Liu
YYYaqi Yang
Yaqi Yang
YHYangjian Hu
Yangjian Hu
ZZZi-Jian Zhao
Zi-Jian Zhao

8 November 2022 in Global Energy Interconnection
Verified
Journal Article
Open access
JSJianxiang Shen
Jianxiang Shen
Wenjia CaiWenjia Cai
Wenjia Cai
XCXiaotong Chen
Xiaotong Chen
XCXing Chen
Xing Chen
ZZZi-Jian Zhao
Zi-Jian Zhao
SZSHAOHUI ZHANG
SHAOHUI ZHANG

17 November 2016 in Molecules
Verified
Journal Article
Open access
PDF file
ZZZi-Jian Zhao
Zi-Jian Zhao
ZZZi-Jian Zhao
Zi-Jian Zhao
JXJing Xiao
Jing Xiao
JWJian-Cheng Wang
Jian-Cheng Wang
Sinomenine is extracted from Sinomenii caulis (a traditional Chinese medicine), and it is used as the active ingredient in rheumatic arthritis treatments. It has been used in clinical applications for decades. However, there are some disadvantages, including low activity in transdermal permeation and a high dosage being clinically required. To overcome these defects, sinomenine was used as a primer, and structural modification was performed. In our study, eight new compounds were screened out by transdermal permeation in vitro and anti-inflammatory response in vitro and in vivo. Compound 1a exhibited the most potent transdermal permeation and anti-inflammatory activity. Based on these results, further development of this compound may be warranted.

5 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
WHWenhui Hao
Wenhui Hao
SCShiying Che
Shiying Che
LJli jinsheng
li jinsheng
JLJingyi Luo
Jingyi Luo
ZQZhang Wan Qiu
Zhang Wan Qiu
WXWeidong Xie
Weidong Xie
Berberine is an isoquinoline alkaloid isolated from Chinese herbal medicines such as Coptis chinensis. It has many pharmacological actions, such as antibacterial, hypoglycemic, anti-inflammatory, and so on. However, due to the low lipophilicity of berberine, it is difficult to penetrate the bacterial cell membrane and also difficult to be absorbed orally and usually needs a relatively high dose to achieve the ideal effect. The purpose of this study is to transform the structure of berberine in order to improve the bioavailability of berberine and reduce the dosage. Moreover, we introduce a pharmacophore named Canagliflozin, a hypoglycemic drug (which was also found to have potential anti-bacterial activity) into BBR to see whether this new compound has more existed activities. We at first connected berberine with Canagliflozin, to form a new compound (BC) and see whether BC has synergic effects. We use microbroth dilution method to determine the minimum inhibitory concentration of BC, determine the bacterial growth with the enzyme labeling instrument, observe the formation of bacterial biofilm with crystal violet staining method, observe the bacterial morphology with field emission scanning electron microscope, and determine the intracellular protein with SDS-PAGE. The above indicators reflect the damage of BC to bacteria. New compound BC was successfully obtained by chemical synthesis. The minimal inhibitory concentration of compound BC on three bacteria was significantly better than that of berberine and canagliflozin alone and the combination of berberine and canagliflozin. Moreover, compound BC has obvious destructive effect on bacterial morphology and biofilm, and the compound also has destructive effect on intracellular proteins. Therefore, new compound BC has broad-spectrum antibacterial activity and the inhibitory effect of BC might play a role by destroying the integrity of biofilm and the intracellular protein of bacteria. In conclusion, we create a new molecular entity of berberine and Canagliflozin chimera and open up a new prospect for berberine derivatives in the treatment of bacterial infection.

23 May 2017 in Synthetic Communications
Verified
Journal Article
Closed access
AHAnguo Hou
Anguo Hou
ZZZi-Jian Zhao
Zi-Jian Zhao
A copper-catalyzed methodology for the preparations of N-aroylated sulfoximines from methylarenes was herein demonstrated. The transformation proceeded with the assistance of external oxidant tert-butyl hydroperoxide, requiring for no additional solvents or ligands. The good compatibility and high efficiency of the newly developed protocol were well described by 21 examples and up to 91% yields. Moreover, the protocol was proved by the control reactions to proceed through a radical pathway. GRAPHICAL ABSTRACT

4 January 2024 in Molecules
Verified
Journal Article
Open access
PDF file
LJli jinsheng
li jinsheng
XHXueli Hou
Xueli Hou
JXJinlong Xiao
Jinlong Xiao
LZLi Zhu
Li Zhu
YDYujie Deng
Yujie Deng
HWHao Wei
Hao Wei
The isoquinoline alkaloid berberine, derived from Coptidis rhizoma, exhibits antibacterial, hypoglycemic, and anti-inflammatory properties. Canagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor. We synthesized compounds B9OC and B9OBU by conjugating canagliflozin and n-butane at the C9 position of berberine, aiming to develop antimicrobial agents for combating bacterial infections worldwide. We utilized clinically prevalent pathogenic bacteria, namely Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, to investigate the antibacterial efficacy of B9OC. This was accomplished through the determination of the MIC80 values, analysis of bacterial growth curves, evaluation of biofilm formation using crystal violet staining, assessment of impact on bacterial proteins via SDS-PAGE analysis, and observation of alterations in bacterial morphology utilizing field emission scanning electron microscopy. Meanwhile, the ADMET of compound B9OC was predicted using a computer-aided method. The findings revealed that B9OC exhibited lower minimal inhibitory concentrations against all three bacteria compared to berberine alone or in combination with canagliflozin. The minimal inhibitory concentrations (MICs) of B9OC against the three experimental strains were determined to be 0.035, 0.258, and 0.331 mM. However, B9OBu exhibited a lower level of antimicrobial activity compared to berberine. The compound B9OC exhibits a broad spectrum of antibacterial activity by disrupting the integrity of bacterial cell walls, leading to cellular rupture and the subsequent degradation of intracellular proteins.